PAB
from announcement:
Patrys Acquires License to Novel Nucleus- Penetrating Antibody Assets Developed at Yale University
- Acquisition provides Patrys with license rights to a portfolio of novel anti-DNA antibodies that penetrate into cell nuclei
- Novel pre-clinical oncology assets and platform have multiple potential applications to treat a range of cancers
PAB from announcement: Patrys Acquires License to Novel Nucleus-...
-
- There are more pages in this discussion • 113 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)